Description
On October 23, the Food and Drug Administration (FDA) approved trabectedin for the treatment of two subtypes of soft tissue sarcomas: liposarcoma and leiomyosarcoma. The approval is for patients whose cancers are advanced or cannot be removed by surgery and who have already been treated with anthracycline-based chemotherapy.
References:
FDA Approves Trabectedin to Treat Two Types of Soft Tissue Sarcoma